Stock AnalizHarrow, Inc. HROW
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Harrow, Inc. (HROW) is a healthcare company listed in the US with a market value of about $1.1B. In the twelve months to September 30, 2026 it had revenue of $303M and net income of -$28M, a net margin of -9.4%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 41% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 67% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $303M | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M |
| Net income | -$28M | -$5M | -$17M | -$24M | -$14M | -$18M | -$3M | $168000 | $15M | -$12M | -$19M |
| Free cash flow | -$20M | $43M | -$24M | $2M | -$892000 | $3M | -$2M | -$518000 | -$1M | -$10M | -$18M |
| EPS (diluted) | $-0.77 | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 | $0.01 | $0.61 | $-0.60 | $-1.50 |
| Net margin | -9.4% | -1.9% | -8.8% | -18.8% | -15.9% | -24.9% | -6.9% | 0.3% | 35.4% | -44.8% | -95.7% |
| ROIC | — | 7.8% | 2.0% | 0.1% | 0.8% | 1.1% | 0.6% | -7.8% | -8.1% | -43.3% | -86.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $62.25, 107% above the current price; targets range from $42.00 to $88.00; the consensus rating is “Strong buy”; expected EPS is $-0.02 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Harrow stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 67% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Harrow pay a dividend?
Not currently.
Is Harrow a good stock to buy?
We do not give buy or sell advice. Harrow scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.